Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases

• Main Authors: Yusuke Muto (Author), Yumi Kambayashi (Author), Hiroshi Kato (Author), Satoshi Fukushima (Author), Takamichi Ito (Author), Takeo Maekawa (Author), Yasuhiro Fujisawa (Author), Koji Yoshino (Author), Hiroshi Uchi (Author), Shigeto Matsushita (Author), Yuki Yamamoto (Author), Ryo Amagai (Author), Kentaro Ohuchi (Author), Akira Hashimoto (Author), Taku Fujimura (Author)
• Format: Book
• Published: Medical Journals Sweden, 2022-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Anti-PD-1 antibodies (Abs) are among the optimal adjuvant therapies for melanoma at high risk of recurrence, especially BRAF wild-type melanoma, but the anti-tumour effects of anti-PD-1 Abs in the adjuvant setting for acral melanoma have not been evaluated previously. The aim of this study was to an...